To hear about similar clinical trials, please enter your email below
Trial Title:
The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma
NCT ID:
NCT05576571
Condition:
Serum Tumor Markers
Conditions: Official terms:
Carcinoma, Hepatocellular
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Met-score
Description:
methylation analysis
Arm group label:
HCC case
Summary:
Patients with liver cancer expected to undergo radiofrequency ablation or transvascular
embolization. Relevant tumor markers (AFP and methylation analysis) were performed. The
two data are then counted and compared.
Detailed description:
The subjects of this study were patients who were diagnosed with liver cancer by
physicians based on AASLD clinical criteria or pathological biopsy.
Patients are those who received radiofrequency ablation or transvascular embolization in
National Taiwan University Hospital. Which excludes weakness and inability to cooperate
Patients with blood test, under the condition of fully informed consent, complete blood
test related tumor indicators (AFP and methylation analysis). The two data are then
counted Compare.
Criteria for eligibility:
Study pop:
Patients diagnosed with liver cancer by AASLD clinical criteria or pathological sections
are planned to receive treatment at National Taiwan University Hospital Liver local
treatment such as radiofrequency ablation or transvascular embolization.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Patients diagnosed with liver cancer by AASLD clinical criteria or pathological
sections are planned to receive treatment at National Taiwan University Hospital
Liver local treatment such as radiofrequency ablation or transvascular embolization.
2. Be over 20 years old.
3. Under the condition of informed consent, willing to sign the consent form of the
subjects.
Exclusion Criteria:
1. Patients who are weak and unable to cooperate with blood test.
2. Kidney dysfunction, serum creatinine greater than 1.5mg/dl, it is judged that
computer tomography or MRI cannot be performed Vibrate the injector.
Gender:
All
Minimum age:
20 Years
Maximum age:
85 Years
Locations:
Facility:
Name:
National Taiwan University Hospital
Address:
City:
Taipei
Country:
Taiwan
Start date:
October 16, 2020
Completion date:
December 31, 2022
Lead sponsor:
Agency:
National Taiwan University Hospital
Agency class:
Other
Source:
National Taiwan University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05576571
